Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition

Inflammatory Bowel Diseases

Volumn 20, Issue 5, 2014, Pages 861-871

  Gerasimidis, Konstantinos ^a,b   Bertz, Martin ^a,c   Hanske, Laura ^c   Junick, Jana ^c   Biskou, Olga ^a   Aguilera, Margarita ^d   Garrick, Vikki ^b   Russell, Richard K ^a,b   Blaut, Michael ^d   McGrogan, Paraic ^a,b   Edwards, Christine A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

Crohn's disease; Enteral nutrition; Gut microbiota; Pediatrics; Short chain fatty acids

Indexed keywords

ACETIC ACID; AMMONIA; BUTYRIC ACID; CALGRANULIN; HEPTANOIC ACID DERIVATIVE; HEXANOIC ACID; ISOBUTYRIC ACID; ISOVALERIC ACID; LACTIC ACID; OCTANOIC ACID; PROPIONIC ACID; VALERIC ACID; BIOLOGICAL MARKER;

ADOLESCENT; ARTICLE; BACTEROIDES; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIET; ENTERIC FEEDING; FAECALIBACTERIUM PRAUSNITZII; FECES; FEMALE; HUMAN; INTESTINE FLORA; MALE; METABOLITE; MICROBIAL DIVERSITY; MICROFLORA; PATHOGENESIS; PEDIATRIC CROHN DISEASE; PH; PRESCHOOL CHILD; PREVOTELLA; PRIORITY JOURNAL; SCHOOL CHILD; WATER CONTENT; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; FOLLOW UP; GASTROINTESTINAL TRACT; METABOLISM; METABOLOMICS; MICROBIOLOGY; PROGNOSIS; REMISSION;

ADOLESCENT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CROHN DISEASE; ENTERAL NUTRITION; FECES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; MALE; METABOLOMICS; PROGNOSIS; REMISSION INDUCTION;

EID: 84902179457     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000023     Document Type: Article

References (39)

1. Cameron FL, Gerasimidis K, Papangelou A, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease. Aliment Pharmacol Ther. 2013;37: 622-629.
2. Beattie RM, Bentsen BS, MacDonald TT. Childhood Crohn's disease and the efficacy of enteral diets. Nutrition. 1998;14:345-350.
3. Ruemmele FM, Roy CC, Levy E, et al. Nutrition as primary therapy in pediatric Crohn's disease: fact or fantasy? J Pediatr. 2000;136:285-291.
4. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
5. Sartor RB. Key questions to guide a better understanding of hostcommensal microbiota interactions in intestinal inflammation. Mucosal Immunol. 2011;4:127-132.
6. Whelan K, Judd PA, Preedy VR, et al. Enteral feeding: the effect on faecal output, the faecal microflora and SCFA concentrations. Proc Nutr Soc. 2004;63:105-113.
7. Lionetti P, Callegari ML, Ferrari S, et al. Enteral nutrition and microflora in pediatric Crohn's disease. JPEN J Parenter Enteral Nutr. 2005;29: S173-S175.
8. Leach ST, Mitchell HM, Eng WR, et al. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther. 2008;28:724-733.
9. Shiga H, Kajiura T, Shinozaki J, et al. Changes of faecal microbiota in patients with Crohn's disease treated with an elemental diet and total parenteral nutrition. Dig Liver Dis. 2012;44:736-742.
10. Jia W, Whitehead RN, Griffiths L, et al. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? FEMS Microbiol Lett. 2010;310:138-144.
11. Tjellstrom B, Hogberg L, Stenhammar L, et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol. 2012;47:1454-1459.
12. Buchanan E, Gaunt WW, Cardigan T, et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30:501-507.
13. Gerasimidis K, Talwar D, Duncan A, et al. Impact of exclusive enteral nutrition on body composition and circulating micronutrients in plasma and erythrocytes of children with active Crohn's disease. In flamm Bowel Dis. 2012;18:1672-1681.
14. Gerasimidis K, Nikolaou CK, Edwards CA, et al. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2011;45:234-239.
15. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
16. Laurentin A, Edwards CA. Differential fermentation of glucose-based carbohydrates in vitro by human faecal bacteria-a study of pyrodextrinised starches from different sources. Eur J Nutr. 2004;43: 183-189.
17. Strocchi A, Furne JK, Levitt MD. A modification of the methylene blue method to measure bacterial sulfide production in feces. J Microbiol Methods. 1992;15:75-82.
18. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. In flamm Bowel Dis. 2006; 12:106-111.
19. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut. 2003;52:237-242.
20. Vetrovsky T, Baldrian P. The variability of the 16S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. PLoS One. 2013;8:e57923.
21. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.
22. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105:16731-16736.
23. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. In flamm Bowel Dis. 2009;15:1183-1189.
24. Hansen R, Berry SH, Mukhopadhya I, et al. The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: the BISCUIT study. PLoS One. 2013;8:e58825.
25. Benus RF, van der Werf TS, Welling GW, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr. 2010;104:693-700.
26. Santhanam S, Venkatraman A, Ramakrishna BS. Impairment of mitochondrial acetoacetyl CoA thiolase activity in the colonic mucosa of patients with ulcerative colitis. Gut. 2007;56:1543-1549.
27. Roediger WE. The colonic epithelium in ulcerative colitis: an energydeficiency disease? Lancet. 1980;2:712-715.
28. Thibault R, De CP, Daly K, et al. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology. 2007;133:1916-1927.
29. Moore JW, Babidge W, Millard S, et al. Effect of sulphide on short chain acyl-CoA metabolism in rat colonocytes. Gut. 1997;41:77-81.
30. Levine J, Ellis CJ, Furne JK, et al. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol. 1998;93:83-87.
31. Jorgensen J, Mortensen PB. Hydrogen sulfide and colonic epithelial metabolism: implications for ulcerative colitis. Dig Dis Sci. 2001;46: 1722-1732.
32. Moore J, Babidge W, Millard S, et al. Colonic luminal hydrogen sulfide is not elevated in ulcerative colitis. Dig Dis Sci. 1998;43:162-165.
33. Geypens B, Claus D, Evenepoel P, et al. Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut. 1997;41:70-76.
34. Lewis S, Cochrane S. Alteration of sulfate and hydrogen metabolism in the human colon by changing intestinal transit rate. Am J Gastroenterol. 2007;102:624-633.
35. Fiorucci S, Distrutti E, Cirino G, et al. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology. 2006;131: 259-271.
36. Fiorucci S, Orlandi S, Mencarelli A, et al. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol. 2007;150:996-1002.
37. El OL, Flourie B, Bruley d V, et al. Relations between transit time, fermentation products, and hydrogen consuming flora in healthy humans. Gut. 1996;38:870-877.
38. Belenguer A, Duncan SH, Holtrop G, et al. Impact of pH on lactate formation and utilization by human fecal microbial communities. Appl Environ Microbiol. 2007;73:6526-6533.
39. Whelan K, Judd PA, Preedy VR, et al. Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. J Nutr. 2005;135:1896-1902.